Afrezza

It’s been a long road for MannKind Corporation (NASDAQ: MNKD) and its Afrezza inhalable insulin product. However, a generous new FDA label this week may be the light at the end of the tunnel. Here’s a look at inhalable insulin’s long journey and what the new FDA ruling means for...

Despite a more than 200-percent gain in MannKind Corporation (NASDAQ: MNKD)'s stock over the past month alone analysts at H.C. Wainwright see even further upside ahead. The firm's Oren Livnat initiates coverage of MannKind's stock with a Buy rating and $7 price target, which represents a gain of...

MannKind Corporation (NASDAQ: MNKD) investors haven’t had much to cheer about lately, with the stock down more than 80 percent in the past three years. However, this week provided investors with a bit of optimism and traders with a huge opportunity for profits. What Happened? MannKind...

Biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) is "making progress" in developing a less costly alternative to Mylan NV (NASDAQ: MYL)'s EpiPen. According to Connecticut-based News Times, MannKind's local manufacturing facility employs around 150 people in the city and plays a key...

The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." FBR: Upgrading Sprint David Dixon of FBR & Co. upgraded shares of Sprint Corp (NYSE: S) to Outperform from Market Perform with...

MannKind Corporation (NASDAQ: MNKD) fell more than 7 percent after the company acknowledged it hasn't hit the break-even point for its inhaled insulin product Afrezza. "These low volumes make it painful because the margins aren't there," Chief Financial Officer Matthew J. Pfeffer said at a Goldman...

In a report published Thursday, RBC Capital Markets analyst Adnan Butt commented that MannKind Corporation (NASDAQ: MNKD) has seen its Afrezza slow to take off and first quarter sales are likely to miss consensus estimates. Butt noted that the consensus estimate for MannKind is approximately $3.9...

U.S. markets managed to squeeze out small gains in lighter than normal volume, as geopolitical tensions may be calming down. Russia President Vladimir Putin said that the country will coordinate with the International Red Cross to send humanitarian aid to Ukraine. Meanwhile, Palestinians and...

U.S. stocks were little changed as the second quarter comes to an end. Investors and traders are likely spending the last day of the quarter the same way they did to ring in the quarter: questioning the direction of the U.S. economy and wondering what is in store in the coming quarter. One...

When it comes to biotech stocks, investors are always hoping for that drug approval that will make their stock “pop." Unfortunately, it is difficult to see such an event coming. Or is it? In less than two short months, MannKind (NASDAQ: MNKD) shareholders will finally receive the...